Skip to main content
SpringerLink
Log in
Book cover

Les cancers digestifs pp 219–240Cite as

Tumeurs endocrines digestives et pancréatiques

  • Chapter

Part of the book series: Oncologie Pratique ((ONCOLPRAT))

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Lepage C, Bouvier A, Phelip J et al. (2003) Incidence et prise en charge des tumeurs endocrines malignes: étude de population en Côte-d’Or et Saône-et-Loire de 1976 à 1999. Gastroenterol Clin Biol 27(HS1): A162

    Google Scholar 

  2. Couvelard A, Felce-Dachez M, Degott C (2003) Classification histologique des tumeurs endocrines du pancréas. Gastroenterol Clin Biol 27: 15–9

    Google Scholar 

  3. Solcia E, Klöppel G, Sobin L (2000) Histological typing of endocrine tumours. 2nd ed. Berlin: World Health Organization — International Histological Classification of Tumours

    Google Scholar 

  4. Aparicio T, Baudin E, Rougier P et al. (1996) Étude des marqueurs dans les tumeurs endocrines du pancréas. Gastroenterol Clin Biol 20: A34

    Google Scholar 

  5. Corleto VD, Panzuto F, Falconi M et al. (2001) Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 33: 217–21

    Article  CAS  PubMed  Google Scholar 

  6. Cadiot G, Lebtahi R, Sarda L et al. (1996) Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 111: 845–54

    Article  CAS  PubMed  Google Scholar 

  7. Verges B, Boureille F, Goudet P et al. (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87: 457–65

    Article  CAS  PubMed  Google Scholar 

  8. Cadiot G, Vuagnat A, Doukhan I et al. (1999) Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Étude des Neoplasies Endocriniennes Multiples (GENEM et Groupe de recherche et d’étude du syndrome de Zollinger et Ellison (GRESZE). Gastroenterology 116: 286–93

    Article  CAS  PubMed  Google Scholar 

  9. Lemmens I, Van de Ven WJ, Kas K et al. (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 6: 1177–83

    Article  CAS  PubMed  Google Scholar 

  10. Krenning EP, Kwekkeboom DJ, Bakker WH et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716–31

    Article  CAS  PubMed  Google Scholar 

  11. Cadiot G, Bonnaud G, Lebtahi R et al. (1997) Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut 41: 107–14

    CAS  PubMed  Google Scholar 

  12. Ruszniewski P, Amouyal P, Amouyal G et al. (1995) Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 117: 629–35

    CAS  PubMed  Google Scholar 

  13. (2003) Que faire devant un cancer digestif en 2003? Recommandations de la Fédération francophone de cancérologie digestive (FFCD). Seconde partie. Gastroenterol Clin Biol 27: 43–58

    Google Scholar 

  14. Hellman P, Lundstrom T, Ohrvall U et al. (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26: 991–7

    PubMed  Google Scholar 

  15. Tomassetti P, Migliori M, Caletti GC et al. (2000) Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343: 551–4

    Article  CAS  PubMed  Google Scholar 

  16. Guillem P, Vlaeminck-Guillem V, Leteurtre E et al. (2002) Tumeurs endocrines fundiques sur gastrite atrophique: intérêt de l„antrectomie. Gastroenterol Clin Biol 26: 782–5

    PubMed  Google Scholar 

  17. Zyromski NJ, Kendrick ML, Nagorney DM et al. (2001) Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg 5: 588–93

    Article  CAS  PubMed  Google Scholar 

  18. Madeira I, Terris B, Voss M et al. (1998) Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43: 422–27

    CAS  PubMed  Google Scholar 

  19. Johanson V, Tisell LE, Olbe L et al. (1999) Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin. Br J Cancer 80: 1259–61

    Article  CAS  PubMed  Google Scholar 

  20. Que FG, Nagorney DM, Batts KP et al. (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169: 36–42; discussion 42-3

    Article  CAS  PubMed  Google Scholar 

  21. Carty S, Jensen R, Norton J (1992) Prospective study of aggressive resection of metastatic endocrine tumors. Surgery 112: 1024–32

    CAS  PubMed  Google Scholar 

  22. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334: 246–54

    Article  CAS  PubMed  Google Scholar 

  23. Ruszniewski P, Ducreux M, Chayvialle JA et al. (1996) Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 39: 279–83

    CAS  PubMed  Google Scholar 

  24. Rubin J, Ajani J, Schirmer W et al. (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17: 600–6

    CAS  PubMed  Google Scholar 

  25. Gorden P, Comi RJ, Maton PN, Go VL (1989) NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110: 35–50

    CAS  PubMed  Google Scholar 

  26. O’Toole D, Ducreux M, Bommelaer G et al. (2000) Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88: 770–6

    CAS  PubMed  Google Scholar 

  27. Shojamanesh H, Gibril F, Louie A et al. (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94: 331–43

    Article  CAS  PubMed  Google Scholar 

  28. Hejna M, Schmidinger M, Raderer M (2002) The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13: 653–68

    Article  CAS  PubMed  Google Scholar 

  29. Aparicio T, Ducreux M, Baudin E et al. (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37: 1014–9

    Article  CAS  PubMed  Google Scholar 

  30. Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79: 108–18

    CAS  PubMed  Google Scholar 

  31. Moertel C, (1987) An odyssey in the land of small tumors. J Clin Oncol 5: 1503–22

    Google Scholar 

  32. Moertel CG, Lavin PT, Hahn RG (1982) Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 66: 1567–9

    CAS  PubMed  Google Scholar 

  33. Ramanathan RK, Cnaan A, Hahn RG et al. (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12: 1139–43

    Article  CAS  PubMed  Google Scholar 

  34. Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21: 36–8

    Article  CAS  PubMed  Google Scholar 

  35. Bajetta E, Ferrari L, Procopio G et al. (2002) Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13: 614–21

    CAS  PubMed  Google Scholar 

  36. Rougier P, Oliveira J, Ducreux M et al. (1991) Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. Eur J Cancer 27: 1380–2

    CAS  PubMed  Google Scholar 

  37. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189–94

    CAS  PubMed  Google Scholar 

  38. Moertel C, Lefkopoulos M, Johnsson LA (1992) Streptozocin-doxorubicin, streptozocinfluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519–23

    CAS  PubMed  Google Scholar 

  39. Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86: 944–8

    CAS  PubMed  Google Scholar 

  40. Ruszniewski P, Hammel P, Tigaud J et al. (2002) Chimiothérapie systémique chez les malades atteints de tumeurs endocrines digestives (TED): une efficacité à réviser. Gastroenterol Clin Biol 26, HS1

    Google Scholar 

  41. Delaunoit T, Ducreux M, Boige V et al. (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40: 515–20

    Article  CAS  PubMed  Google Scholar 

  42. Ducreux M, Kergoat P, Boige V et al. (2002) Évaluation de l’efficacité de la chimiothérapie par LV5FU2-Campto dans les tumeurs neuroendocrines metastasées. Gastroenterol Clin Biol 26: HS1

    Google Scholar 

  43. Frame J, Kelsen D, Kemeny N et al. (1988) A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol 11: 490–5

    CAS  PubMed  Google Scholar 

  44. Haller DG, Schutt A, Dayal Y et al. (1990) Chemotherapy for metastatic carcinoid tumors: an ECOG phase II-III trial. Proc Am Soc Clin Oncol 9: 102

    Google Scholar 

  45. Gonzalez MA, Biswas S, Clifton L, Corrie PG (2003) Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89: 455–6

    Article  CAS  PubMed  Google Scholar 

  46. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68: 227–32

    CAS  PubMed  Google Scholar 

  47. Mitry E, Baudin E, Ducreux M et al. (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351–5

    Article  CAS  PubMed  Google Scholar 

  48. Oberg K, Funa K, Alm G (1983) Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 309: 129–33

    CAS  PubMed  Google Scholar 

  49. Faiss S, Pape UF, Bohmig M et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689–96

    Article  CAS  PubMed  Google Scholar 

  50. Jacobsen MB, Hanssen LE, Kolmannskog F et al. (1995) Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 30: 789–96

    CAS  PubMed  Google Scholar 

  51. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE (1992) Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 10: 1647–50

    Google Scholar 

  52. Frank M, Klose KJ, Wied M et al. (1999) Combination therapy with octreotide and alphainterferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94: 1381–7

    CAS  PubMed  Google Scholar 

  53. Venook AP (1999) Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 11: 38–41

    Article  CAS  PubMed  Google Scholar 

  54. Dominguez S, Denys A, Madeira I et al. (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12: 151–7

    CAS  PubMed  Google Scholar 

  55. Roche A, Girish BV, de Baere T et al. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13: 136–40

    PubMed  Google Scholar 

  56. Dominguez S, Denys A, Menu Y, Ruszniewski P (1999) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol 31Suppl 2: S 213–5

    Google Scholar 

  57. Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World Journal of Surgery 26: 985–90

    Article  PubMed  Google Scholar 

  58. Mukherjee JJ, Kaltsas GA, Islam N et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55: 47–60

    Article  CAS  Google Scholar 

  59. Otte A, Mueller-Brand J, Dellas S et al. (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351: 417–8

    Article  CAS  PubMed  Google Scholar 

  60. Buscombe JR, Caplin ME, Hilson AJ (2003) Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44: 1–6

    CAS  PubMed  Google Scholar 

  61. Waldherr C, Pless M, Maecke HR et al. (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43: 610–6

    CAS  PubMed  Google Scholar 

  62. Eriksson B, Skogseid B, Lundqvist G et al. (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65: 1883–90

    CAS  PubMed  Google Scholar 

  63. Ollivier S, Fonck M, Becouarn Y, Brunet R (1998) Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial. Am J Clin Oncol 21: 237–40

    Article  CAS  PubMed  Google Scholar 

  64. Moertel CG, Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327–34

    CAS  PubMed  Google Scholar 

  65. Engstrom PF, Lavin PT, Moertel CG et al. (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2: 1255–9

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. T. Aparicio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Dominguez-Tinajero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Mitry
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Aparicio, T., Dominguez-Tinajero, S., Mitry, E. (2006). Tumeurs endocrines digestives et pancréatiques. In: Les cancers digestifs. Oncologie Pratique. Springer, Paris. https://doi.org/10.1007/2-287-30874-1_12

Download citation

  • DOI: https://doi.org/10.1007/2-287-30874-1_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-22087-6

  • Online ISBN: 978-2-287-30874-1

Publish with us

Policies and ethics

Search

Navigation